Podcasts about co leader

The pause only works if you plan for it. Here's how to get ready to truly rest.Whether you're heading into a sabbatical, PTO, or just a long weekend, this episode helps you actually get ready to rest. Lindsey shares three readiness reflections — Finance, People, and Program — to gauge if your org (and you) can sustain time away.You'll learn how to design an “only-call-me-if” checklist that protects your peace and keeps operations smooth—so you can step away without second-guessing. Then, run a Start–Stop–Continue to help your team prioritize what truly matters, pause what can wait, and sustain the rhythms that make your culture healthy. These simple tools turn time off from something stressful into something strategic.Part of the Power of the Pause series, this conversation reminds nonprofit pros, educators, and helpers everywhere that rest isn't a reward — it's a leadership practice.Episode HighlightsPreparing for a Powerful Pause: The Need for Rest (01:00)Extended Breaks & Sabbaticals: Overcoming Resistance (03:00)Readiness Reflections: Finance, People, Program (04:54)The Role of a Co-Leader & Timing Your Leave (08:46)Somatic Practice: Breathe and Bloom (feat. Marisol Pineda Conde) (10:51)Emergency Checklist: Planning for Critical Issues (13:48)Start, Stop, Continue: Transitioning Responsibility (17:58)Somatic Exercise with Marisol Pineda Conde (21:30)Visualization for Restoration & Setting Intentions (23:50)Affirmations and Reflective Questions for Readiness (27:58)www.weareforgood.com/episode/planforapauseSupport the showBecome a Member and Get All-Access to Everything We Are For Good!Experience the Impact Uprising Membership by We Are For Good: an ecosystem to learn, connect + grow in the power of a value-aligned community. Members gather monthly with Jon + Becky at exclusive members-only meetups + get video access to all new podcast episodes in an ad-free experience + so much more! Learn more + join us at weareforgood.com.Say hi

Te Pāti Māori's pledged to concentrate on policy - and listen more. The party held its promised reset event at Parliament this afternoon, reflecting on its history and looking towards next year's election. Former Te Pāti Māori co-leader Te Ururoa Flavell says a party reset would be a good move. "What that means in terms of translating into policy gains, what it means in terms of taking an approach to the country and reflecting the original kaupapa for Te Pāti Māori - I think still remains to be seen." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Donagh Humphreys, Head of Social for Ogilvy Ireland; Colm Brophy, Minister of State for Migration and Fine Gael TD for Dublin South-West; Louise O'Reilly, Sinn Féin TD for Dublin Fingal West; Michael Collins, Co-Leader of Independent Ireland TD for Cork South-West

Colm Brophy, Minister of State for Migration and Fine Gael TD for Dublin South-West; Louise O'Reilly, Sinn Féin TD for Dublin Fingal West; Michael Collins, Co-Leader of Independent Ireland TD for Cork South-West

Colm Brophy, Minister of State for Migration and Fine Gael TD for Dublin South-West; Louise O'Reilly, Sinn Féin TD for Dublin Fingal West; Michael Collins, Co-Leader of Independent Ireland TD for Cork South-West

Garry Martin, Director of Emergency Services for Donegal Co Council; Colm Brophy, Minister of State for Migration and Fine Gael TD for Dublin South-West; Louise O'Reilly, Sinn Féin TD for Dublin Fingal West; Michael Collins, Co-Leader of Independent Ireland TD for Cork South-West

Wade Sutton (PwC's Washington National Tax Services - International Tax Services Leader) is joined by Pat Brown, an ITS Partner and Co-Leader of PwC's Washington National Tax Services practice. Pat previously served as the US Treasury's Associate International Tax Counsel and has been a frequent guest on the podcast. Wade and Pat take a deeper dive into the future of Pillar Two, focusing on the G7's ‘side-by-side' agreement.  They highlight the historical positions of previous US administrations, why  proposed Section 899  was dropped from OBBBA, US dissatisfaction with the lack of accommodations for the US GILTI regime and R&D tax credits, the OECD process and how countries could implement changes, and the potential for simplification including a potential permanent safe harbor. Finally, they look to the future and what may happen next. 

A former Māori Party leader says he can't make sense of MP Tākuta Ferris' controversial race comments. Ferris posted a photo of Labour volunteers stating their ethnicities and wrote they were campaigning to take a Māori seat from Māori in the Tamaki Makaurau by-election. The party apologised, but Ferris stood by his comments in a second social media video. Te Ururoa Flavell says the party has a history of inclusivity and explained many of their candidates in the general sense weren't Māori - being Pasifika, Chinese and Korean. LISTEN ABOVESee omnystudio.com/listener for privacy information.

The Tawaki Project based at the University of Otago and driven by the mahi of international researchers, has taken a deep-dive into the population genetics of three Aotearoa crested penguin species – tawaki/Fiordland penguins, erect-crested penguins, and Eastern rockhopper penguins. Findings reveal how genetic health and marine habitat changes have impacted these species. For this week's Green Desk, Host Sara spoke with co-leader of the project, Dr Thomas Mattern about what the study learned about these penguin populations, starting with a general overview of the research

The Tawaki Project based at the University of Otago and driven by the mahi of international researchers, has taken a deep-dive into the population genetics of three Aotearoa crested penguin species – tawaki/Fiordland penguins, erect-crested penguins, and Eastern rockhopper penguins. Findings reveal how genetic health and marine habitat changes have impacted these species. For this week's Green Desk, Host Sara spoke with co-leader of the project, Dr Thomas Mattern about what the study learned about these penguin populations, starting with a general overview of the research

The Tawaki Project based at the University of Otago and driven by the mahi of international researchers, has taken a deep-dive into the population genetics of three Aotearoa crested penguin species – tawaki/Fiordland penguins, erect-crested penguins, and Eastern rockhopper penguins. Findings reveal how genetic health and marine habitat changes have impacted these species. For this week's Green Desk, Host Sara spoke with co-leader of the project, Dr Thomas Mattern about what the study learned about these penguin populations, starting with a general overview of the research

Debbie Ngarewa-Packer is known for unapologetically fighting for the rights of Māori. The co-leader of Te Pati Māori never shies away from speaking her mind -- especially when it comes to social and climate justice. Since becoming co-leader in 2020, and MP for Te Tai Hauauru at the last election, she’s been suspended from Parliament and criticised the coalition’s “intent to dismantle indigenous rights”. At the last election, the party won six electorate seats – its best result yet. So, Today on The Front Page, Debbie Ngarewa-Packer is with us to take us through how the party’s gearing up for Election 2026 and how they’ll appeal to the masses – or, if they even want to? Follow The Front Page on iHeartRadio, Apple Podcasts, Spotify or wherever you get your podcasts. You can read more about this and other stories in the New Zealand Herald, online at nzherald.co.nz, or tune in to news bulletins across the NZME network. Host: Chelsea DanielsEditor/Producer: Richard MartinProducer: Jane YeeSee omnystudio.com/listener for privacy information.

Everything Aspiring Franchisees Need to Know Before Signing the Dotted LineOn this insightful episode of The Franchise Academy Podcast, host Tom Scarda welcomes Michael Iannuzzi, Certified Public Accountant, Certified Franchise Executive, and Co-Leader of Citrin Cooperman's Franchising Practice. Together, they demystify one of the most critical documents in the franchise world—the Franchise Disclosure Document (FDD).Whether you're a first-time franchise buyer or looking to expand your portfolio, this episode will give you a clearer understanding of:What audited financial statements in the FDD really meanThe right questions to ask when your target market isn't included in Item 19Whether unverified information in the FDD holds any valueHow to contact current and former franchisees using the list at the back of the FDDWhy you should read the FDD multiple times and take notes before making a decisionHow to get Tom's exclusive FDD Cheat Sheet with over 30 essential questions for franchiseesMichael shares powerful industry insights gained from years of experience working with top franchisors and multi-unit franchisees. You'll learn how to approach the FDD with confidence, spot red flags, and perform due diligence like a pro.

Since the Government took office in January, the number of children awaiting scoliosis surgery has risen from 112 to 131, despite 303 procedures being carried out by Children's Health Ireland (CHI) up to July. CHI noted that the list is constantly changing as patients are added and removed.In 2017, then–Health Minister Simon Harris pledged that no child would wait more than four months for surgery. That target remains unmet, and there have since been calls for the Tánaiste to resign on the back of his failed promises.Why are children waiting so long for surgeries, and what needs to be done to improve these wait times for children and their families?Joining Andrea to discuss is Bernard Mulvany, Advocate with Access for All Ireland, Co-Leader of the Spina Bifida Advocacy Group, Una Knightly and Carolann Walsh, whose 5-year-old daughter is currently waiting for an MRI scan for scoliosis.

Yesterday was National Whistleblower Day. DOJ has a new program that offers payment to whistleblowers who submit reports of antitrust violations that are later proved successful. But the program is complicated, with lots of conditions on those payments. Here to help us sort through the details is partner at Shepherd Mulling and Co-Leader of their Antitrust and Competition Practice Group, Ann O'Brien. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Green Party says the Government needs to follow up its words on Gaza with action. A group of nations, including New Zealand, have signed on to a declaration calling for a ceasefire and condemning Israeli attacks on Palestinians seeking aid. Greens co-leader Chlöe Swarbrick says we should sanction Israel to the same degree as Russia. She told Ryan Bridge words are not enough. Swarbrick says there's large scale starvation and Palestinians can't eat words. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Doug McHoney (PwC's International Tax Services Global Leader) is joined by Pat Brown, an international tax partner and Co-Leader of PwC's Washington National Tax Services practice and former Deputy Assistant Secretary for Tax Policy at the US Treasury. In part three of Doug's three-part OBBBA discussion with Pat, they discuss the newly enacted OB3 reconciliation law, focusing on its permanent corporate and individual tax provisions, the recalibration of bonus depreciation, Section 174 expensing and Section 163(j); the Senate's redesign of GILTI, FDII and BEAT; Inflation Reduction Act rollbacks; Treasury's last-minute removal of Section 899; and the G7's surprise accord intended to exempt US-parented groups from Pillar Two's IIR and UTPR while elevating QDMTTs and compliance simplification. They map the procedural and legislative steps still needed, potential timing gaps, and why multinational groups must keep Pillar Two compliance front-of-mind.  

Doug McHoney (PwC's International Tax Services Global Leader) is joined on June 24, 2025, by Pat Brown, an International Tax Partner and Co-Leader of PwC's Washington National Tax Services practice. Pat previously served as the US Treasury's Deputy International Tax Counsel and has been a frequent guest on the podcast. Doug and Pat start where they left off discussing 'One Big Beautiful Bill' (OB3), in wake of the US Senate Finance Committee Chairman's Substitute Amendment. They discuss the next steps in the legislative timeline including the impending July 4th deadline, the impact of the Byrd rule, as well as the many changes to both the business and international provisions. They focus on the major changes to Section 899, global intangible low-taxed income (GILTI), foreign derived intangible income (FDII), and the base erosion and anti-abuse tax (BEAT).  

JCO PO author Dr. Philip Philip at Henry Ford Cancer Institute and Wayne State University shares insights into his JCO PO article, “Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.” Host Dr. Rafeh Naqash and Dr. Philip discuss how prospective trials are required to clarify the role of ctDNA as a valid surrogate end point for progression-free or overall survival in GI cancers. Transcript Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are excited to be joined by Dr. Philip Philip, Chair of Hematology and Oncology, as well as leader of GI and Neuroendocrine Oncology. He's also the Professor of Oncology and Pharmacology, as well as Co-Leader of the Pancreatic Cancer Program and Medical Director of the Cancer Clinical Trial and Translational Research Office at the Henry Ford Cancer Institute at Wayne State University. Dr. Philip is also the Senior Corresponding Author of the JCO Precision Oncology article entitled, "Incorporating Circulating Tumor DNA Testing into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group." At the time of this recording, our guest's disclosures will be linked in the transcript. Dr. Philip, welcome to our podcast, and thank you so much for joining us today. Dr. Philip Philip: Thank you so much, Dr. Naqash, for providing me this opportunity to be discussing this with you. Dr. Rafeh Naqash: This is a very timely and interesting topic. We've done a couple of podcasts on ctDNA before, but none that is an opinion piece or a guidance piece based on what you guys have done. Could you tell us what led to this perspective piece or guidance manuscript being published? There is some background to this. Could you tell us, for the sake of our listeners, what was the initial thought process of why you all wanted to do this? Dr. Philip Philip: The major reason for this was the fact that investigators were considering using ctDNA as a primary endpoint in clinical trials. Obviously, you hear my focus will be on gastrointestinal cancers. So, the idea was, can we use ctDNA instead of using the traditional endpoints such as disease-free survival, progression-free survival, or overall survival? And the question was, do we have enough data to support that in patients with gastrointestinal cancers? Now, the article obviously goes over some review of the data available, but the core of the article was not to do a comprehensive review of ctDNA use and the evidence so far, although we used that in really putting our recommendations. So, we really had to evaluate available data. But the focus was, what are the gaps? What do we need to do? And are we ready to use ctDNA as a primary endpoint in clinical trials? Dr. Rafeh Naqash: Thank you for giving us that background. Obviously, a very broad, complicated topic with a bunch of emerging data that you've highlighted. But most importantly, for the sake of, again, trainees and listeners, could you help us understand the difference between tumor-informed and non-tumor-based ctDNA assessments? Dr. Philip Philip: Sure. So, the tumor-informed is simply meaning that you're taking the genomic makeup or the DNA fingerprint of the cancer in a given patient, and you create a profile, and then use that profile to see whether that DNA is present in the blood. So, it's very simple. It's like barcoding DNA and then going and looking for it in the blood, which means that you have to have the primary tumor. When I say primary tumor, you need to have the tumor to start off with. It doesn't really apply, maybe easily, if you just have a fine-needle aspirate and things like that. So, you really have to have a good amount of the tumor for you to be able to do that. So, that's a tumor-informed, and from the name, you can easily understand how it's done, compared to the other one, which is uninformed, whereby off-the-shelf probes are used to look for tumor DNA. And again, they're based on prior experience and prior identification of the key DNA changes that will be seen in tumors. So, that's the difference between the two in terms of the principle of the test. The uninformed will not require you to send the original tumor that you're trying to test. However, the informed, you do. The turnaround time is, again, a bit different because, as you would expect, it's shorter in the uninformed. And the reason for that, again, is the initial preparation of the profile that is going to be used in the future when you do serial testing. The sensitivity has been a bit of a discussion. Initially, people have thought that tumor-informed assays are more sensitive, more specific, more sensitive, et cetera. But in our review, we come to the conclusion saying that we don't think that's going to be a major difference. And there are obviously improvements happening in both types of assays. The sensitivities have been improving. So, at this point in time, we do feel that you have two types of assays, and we didn't feel strongly about recommending one over the other. Dr. Rafeh Naqash: Thank you for that description. You mentioned something about sensitivity, specificity. Obviously, many of us who have ordered both tumor-informed and tumor-uninformed, we understand the differences with respect to the timing. The tumor-informed one can take more time. The uninformed one, being a sort of a liquid biopsy, may not necessarily have as much of a turnaround time. Could you briefly speak to those limitations or advantages in the context of the two versions? Dr. Philip Philip: I just really want to also highlight that when we say turnaround time, so for the tumor-informed assays, the first assay that we do will be requiring a turnaround time. But once the pattern has been set and the profile has been documented, the subsequent testing doesn't require much in the way of waiting. However, when you're using this for the minimal residual disease, then you have a window of opportunity to work at. That's number one. So, it means that in patients who have resected cancer, you may end up having to wait longer than the tumor-uninformed assay, especially if you don't have easy access to your material for the baseline material to send. And also, what we'd like to do is not do the test immediately after the operation or soon after the operation. Give it some time. There's a window where you can work at, and starting minimally two weeks after the surgery. But in my experience, I'd like to wait at least four weeks just to make sure that we got an accurate reading. Sometimes when you do it very early after surgery, because of the effect of the surgery and the release of the normal DNA is also, it may dilute the tumor DNA, and then you may get a false negative. So, basically, it depends on the clinical situation. And your question is, is one better to be used than the other? I think ultimately, it ends up with the turnaround time not being as much of an issue. It might be in certain situations, depending on when you see the patients after the operation or any definitive treatment you've done and you want to look for minimal residual disease. But in general, I don't think that's going to be a real major issue. Dr. Rafeh Naqash: I remember discussing this with one of the tumor-informed platforms with regards to this barcode you mentioned. They generate a fingerprint of sorts for the tumor on the tissue, then they map it out in the blood and try to assess it longitudinally. And one of the questions and discussions we had was around the fact that most of the time, these barcoded genes are not the driver genes. If you have a KRAS mutant tumor, it's not going to be the KRAS gene that they map out. It's something that is specific. So, is there a possibility that when you are mapping out, let's say, a metastatic tumor where there is truncal and subclonal mutations at different sites, that you capture something that is not necessarily truncal, and that does not necessarily reflect some other metastatic site having a recurrence? So basically, over time, you don't see a specific mutational pattern or the signature on the tumor-informed, and then you see something on the scan which makes you think, "Well, it was not the right test," but actually it could be a different subclone or a clone mutation at a different site. Is there a concept that could help us understand that better? Dr. Philip Philip: I think you raise a very important point. Although, I have to say from my practical experience, that is not a common thing to see. In fact, for some reason, we don't see it that often in any frequency that should, at this point in time, make us concerned about the serial testing. But what you were mentioning is a real challenge which can happen. Now, the question is, how often does the clonal evolution or the divergence happen to the point that it's going to be like a false negative, is what you're saying. At this point in time, we don't really have good information on that, or any good information, practical information. And when we went through the literature and we were looking for the evidence, that wasn't something which was there clearly telling us. Although, this is something that has to be studied further prospectively. And I don't know of a study, but I might be missing it, I don't know of a study which is systematically looking at this. Although it's a very valid hypothesis and theoretical basis for it, but in real life, we still have to see how much does it really interfere with the validity of this kind of testing. Dr. Rafeh Naqash: Which brings us to the more important discussion around your manuscript. And I think that the overarching theme here is the consensus panel that you guys had recommended that ctDNA-based metrics be used as a co-primary endpoint. Could you tell us, for early-phase trials, maybe phase two studies for that matter, could you tell us what were some of the aspects that led to this consensus being formed from your working group? Dr. Philip Philip: Well, there were a number of reasons, in any order of priority, but one of them is we don't have a good sense of dynamics of the ctDNA. And again, remember this article was about gastrointestinal cancers. Maybe we know more about colon cancer, but, or colorectal cancer, but we don't know that well about the upper GI, like gastroesophageal, pancreatic, et cetera. So, we don't know what is the false negative percentages. And in fact, we know that there are certain sites of the disease, metastases, that do not lead to enough shedding of the DNA into the circulation. So, that was something else. I mean, false negativity, not knowing exactly what the dynamics are, especially in different disease types. So, that was another reason, which we felt that it may not be at this time primetime to really have those ctDNA tests as a primary endpoint. We wanted to make sure that, on the other hand, we wanted to make sure that people consider including ctDNA more like a secondary endpoint so that we can gain the information that we're lacking, at least the ones I mentioned to you. So, that was an important point of our discussions and deliberations when we were writing the article. Dr. Rafeh Naqash: And I myself have been on both sides of the aisle where - I treat people with lung cancer, you mentioned appropriately that most of the data that we have for ctDNA is generated from GI cancers, especially colorectal - on the lung cancer side, I myself had a patient with an early-stage cancer, had treatment, surgery, immunotherapy, and then had ctDNA that was tumor-informed, was positive four to five months before the imaging actually showed up. And on the other side, I've also had an individual where early-stage lung cancer, surgery, immunotherapy, and then had PET scans that showed a positive finding, but the ctDNA, tumor-informed ctDNA, was negative multiple times. So, I've seen both aspects of it, and your paper tries to address some of these questions on how to approach a negative, radiologically negative imaging but positive ctDNA potentially, and vice versa. Could you elaborate upon that a little bit? Dr. Philip Philip: Well, obviously, we do see this in practice. Again, I do GI oncology. I have patients who, you do ctDNA. I mean, my advice to anyone, when you order a test, you have to make sure that you know what you're going to do with the test, because that's the most important thing. You get a positive test, you do something. You get a negative test, you do something. But most importantly, our patients who you're following up, they are very anxious for a diagnosis they have that is not- I mean, it's cancer. If you're doing these tests, if we get continuous, repeatedly negative testing, then you really have to also tell the patient that there's a false negativity. And I mentioned to you earlier, there are certain sites of disease, like peritoneal, they may not be producing enough, or there are some tumors, their biology is such that they don't release as much to be detected in the blood. Now, one day we will get maybe a more sensitive test, but I'm talking about the tests we have now. On the other hand, if you get a positive testing, you have to make a distinction for ctDNA in the minimal residual disease situation. If you get a positive test, there is enough evidence that the patient has a worse prognosis. There's evidence for that. No one can dispute that. Again, I'm talking about colorectal cancer where there are a lot of data for that. So, in that situation, there are studies that are looking, if you get a positive test in someone who you're not intending to give any adjuvant treatment, there are studies looking into that, both in terms of intensifying, like chemotherapy, in certain patients. And also, there's work being done, if you have a negative test in someone who has stage III disease, for example, or definitely stage II disease, they may not need to give them chemo. Those things are happening. But in metastatic disease, it's a different situation. Or even in someone who has received surgery, adjuvant chemotherapy, in those patients where they, whether they're now under, in the surveillance mode, those patients, if you have a positive, it may be positive. I had a recent patient like those, eight months before we saw anything on the scans. So, the question is, if you have a positive test, is there any advantage in giving them treatment, systemic treatment? Of course, we're assuming that the PET scan is negative. So, is there really any advantage in giving someone treatment ahead of time, before you see the imaging changes? That kind of data, in my opinion, is not really available or strong. You can always think of it in different ways, explain it in different ways. It's minimal disease, maybe you get a better response. But I don't know if we really can justify at this time. Therefore, in my practice, my own practice, I do not treat just a positive ctDNA. Again, that's different than after surgery when you're thinking of whether to give adjuvant treatment, no adjuvant treatment. But someone who's finished treatments and then you're just serially monitoring the disease, those patients, I do not treat them with chemotherapy. And that was something which, based on the literature we reviewed, there was nothing out there to definitely- I mean, if you see something positive, you will do a scan earlier, you will talk to the patient, examine the patient, whatever. But if there's nothing there, starting a treatment, that's not justified at this point in time. Now, you need to do a study like that. Definitely, you need to do a study. But I can tell you that from my experience, having been involved with study design and all that, it's not an easy trial to do. It's going to be a trial- at a minimum, it will take many patients, it will take longer time to complete, and there are a number of variables there. If someone is willing to put a lot of money into it, it can be done. But I can tell you that that kind of intention to do a study like that has been very much a challenge at this time. Dr. Rafeh Naqash: Of course, as you mentioned, the follow-up time that you need for a study like that is going to be very long to get to meaningful outcomes. Dr. Philip Philip: You need to be very patient to do such a study. But the problem with a very long study is that things change, standard of care changes with time, and the assays will change. So, that's why we don't have that kind of data. I'm not sure if there are people in the community or in the academic centers who do treat based on only positive ctDNA. The other thing is that you really have to always consider the psychological impact of these tests on patients and caregivers. Sometimes it can be really very stressful, burdensome to people to sit there just waiting for the disease to show up on a scan. And therefore, in my opinion, I'm not saying definitely don't use it in that situation, I'm just saying that you have to personalize it also, to see the patient who you would like to do it and then other patients who may not do it, or you think that it's not good for them to do it. And the patient also has to understand the outcome of the test and how you're going to be interpreting it. Dr. Rafeh Naqash: That's a lot of great insights, Dr. Philip, and I know you've been involved in trial designs. I'm sure NCT and cooperative groups are actively thinking and incorporating ctDNA-based metrics as one of the endpoints in their trial. I know of a GU study that's, I think it's an Alliance study, trying to de-escalate treatment based on ctDNA. I have one of my colleagues who's also a GU investigator at OU, he's doing a ctDNA-based, tumor-informed-based de-escalation. So, obviously, more and more data, hopefully, that'll be generated in the next couple of years. Dr. Philip Philip: But remember, these studies are not using it as an endpoint. They're using it as a means of optimizing treatment, which is a bit different. So, as an endpoint, can you do a phase III trial of, let's say, a thousand patients, and your primary endpoint is not survival, but you're saying, "Can I reduce the ctDNA, clear it earlier, or whatever?" That's the sort of thing this article was about. We can't do that at this time. Dr. Rafeh Naqash: I totally understand. Thank you for explaining the difference, and hopefully more to come in this space in the next couple of years. I briefly wanted to touch upon your personal career and journey based on all that you've done and accomplished. Could you tell us about how you started, what your journey has been like, and how that connects with what you're doing right now, including mentoring other trainees and junior faculty? Dr. Philip Philip: Well, when I was in high school, I wanted to be an engineer, but I grew up in Baghdad, and all my friends wanted to do medicine, so I went with the tide, so I did medicine. I don't regret that. I would do it again if I had the opportunity. The reason why I did oncology was, I left the country and did a PhD in clinical pharmacology at the University of London. And that really got me, it was a topic which included, which was on cancer. So, I really got interested in a disease that is really a lot of science, and things are new, or were new at the time. And if I want to look back what I was doing, the beginning of my training in the 80s, second half of the 80s, and now, it's unbelievable how things have changed. But one of the things which I really have to say is that almost all my life I've been in what we call academic institutions. But I firmly believe that for people, whether academic or not, you have to be a very good, astute clinician, because many of the things we do, really, we're trying to put the patients in the center. It's not only doing fancy science, it's to do things that help the patients. And you can bring in bits and pieces of fancy science or less fancy science, but that's something which is really extremely important for us to think about, being a very good clinician, very good doctor, because medicine is a science, whether you're practicing as a solo practitioner or you're part of a large academic center. It's the way you think, the way you interrogate things that you're not sure of, the way you collaborate, the way you learn every day. I mean, at my age, I still don't like to miss any tumor board, because in each tumor board, there's something you learn, even if you think that you know everything. So, that's really the whole thing of it, is that be a very good clinician, be open-minded. Always, you have to think of things that, they look interesting, they look somehow unexplained. Always try to help find the solutions and do that. One of the major things that I feel that people should do is being also very focused on things. I mean, you have to also know what you want to do in the next 5, 10, 15 years. Because although everyone is in it in the same way when we start, but there are different things that drive people, people who want to do more of the formal research, like being an academic-like institution. But there are also a lot of people who are very successful outside of a- what we call an academic setting. In the United States, most people are not working in an academic kind of setting. Although, for me, the distinction between academic and community is getting less and less, because if you think that you do phase I trials in academia only, that's not true, because there are, in fact, in the state of Michigan, the most active phase I doctor is not even in academia, he's in private practice. So, you can do all these things. It's a matter of what you like to do, and you really have to make sure you know what you want to do. Because sometimes people are, especially early on, they get a bit confused, “What I want to do.” There's an issue of doing general oncology versus subspecialist. If you're a subspecialist doing only GI, you have to make sure that you really also have some kind of recognition that you're only a GI oncologist, recognition regional, national, international, but some degree of recognition that you feel that people are coming to you for advice as a second opinion or whatever it is. But again, you have to decide what you think you want to be, how you want to be, because there's a lot of options here between community practice, academic practice, industry, and of course, there's always the administrative thing. Some people tend to be more like going into the line of being an administrator. So, there's a lot of options for you. Dr. Rafeh Naqash: Well, thank you again, Dr. Philip, for those pearls of wisdom. I think that was very insightful. I'm sure all the trainees and early-career investigators will find all that advice very helpful. Thank you again for joining us today. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Philip Philip Disclosures Honoraria: Bayer, Ipsen, incyte, Taiho Pharmaceutical, Astellas Pharma, BioNTech SE, Novocure, TriSalus Life Sciences, SERVIER, Seagen Consulting or Advisory Role: Celgene, Ipsen, Merck, TriSalus Life Sciences, Daiichi Sankyo, SynCoreBio, Taiho Pharmaceutical Speakers' Bureau: Incyte Research Funding: Bayer (Inst), incyte (Inst), Merck (Inst), Taiho Pharmaceutical (Inst), novartis (Inst), Regeneron (Inst), Genentech (Inst), halozyme (Inst), Lilly (Inst), Taiho Pharmaceutical (Inst), merus (Inst), BioNTech SE (Inst) Uncompensated Relationships: Rafael Pharmaceuticals, Caris MPI  

Doug McHoney (PwC's International Tax Services Global Leader) is joined by Pat Brown, an International Tax Partner and Co-Leader of PwC's Washington National Tax Services practice. Pat previously served as the US Treasury's Deputy International Tax Counsel and has been a frequent guest on the podcast. Doug and Pat discuss the legislative and international tax implications of the 'One Big Beautiful Bill', including its procedural path through US Congress under budget reconciliation, and its implications for both domestic and cross-border taxpayers. They explore the bill's temporary business provisions, including TCJA 'orphan' fixes, and the evolving treatment of research expenses, bonus depreciation, and interest deductions. A major focus is Section 899—dubbed the 'super BEAT'—which targets foreign digital services taxes (DSTs), diverted profits taxes (DPTs), and Pillar Two's undertaxed profits rule (UTPR) with steep retaliatory measures. They also analyze the international negotiations around UTPR exemptions, the impact on treaty obligations, and the ongoing debate over treatment of US tax credits—particularly the R&D credit—under global minimum tax rules. 

Atty Maya McCann, co-leader of Fairness for Farmworkers Coalition: the subminimum wage. Hampshire Prof Emeritus of Peace & World Securities Studies, Michael Klare: the Israel-Iran War. Ehmptn Mayor Nicole LaChapelle: “No Kings” protest & antisemitism in the schools. Peace Development Fund's Lora Wondolowski & Jessa McCormack w/ Seeing Rainbow's Nuri.

The Green Party is speaking out over Israel stopping a civilian yacht carrying humanitarian aid to Gaza. Israeli forces intercepted a yacht carrying prominent activists - including Greta Thunberg. Its Foreign Ministry says they're safe, and the cargo will be taken to Gaza. But Green Party co-Leader Marama Davidson says that's not good enough. "We want to see Israel stop shooting at innocent people lining up for a kai and we're calling on the Government to sanction Israel for its violent occupation of Palestine." LISTEN ABOVESee omnystudio.com/listener for privacy information.

The recommended suspension for Te Pāti Māori MPs, Debbie Ngarewa-Packer, Rawiri Waititi, and Hana Rawhiti Maipi-Clarke, over the MP's haka in Parliament during the first reading of the Treaty Principles Bill last year. Co-leaders Ngarewa-Packer and Waititi will be suspended from the House for 21-days, with Maipi-Clarke facing a seven day suspension. This is Parliament's harshest sanctions in the country's history. Prior to this, the longest suspension an MP had faced in Parliament was three days. The debate had previously been delayed so that the MPs could participate in the Budget debate — however, both co-leaders were not present at the debate. During the debate MP Tākuta Ferris said that the debate was not about the haka, but at the heart, it was the House continuing to ignore Te Tiriti o Waitangi and Māori sovereignty, and that the “racism” in the House is hardly being hidden. For our weekly catch-up, News and Editorial Director and Monday Wire Host, Joel, spoke to Te Pāti Māori's Takutai Kemp about the suspension, and what's next for the party. They also discussed NZ First Party Leader Winston Peters' comments regarding Waititi's moko, referring to the MPs moko kanohi as “scribbles”. He was asked to apologise by the Speaker, which he did. But first, they discussed the suspension of the MPs.

The debate on Te Pāti Māori's proposed punishment has been paused until June - but it's still sparked discussion among some. Debate was set to begin today on proposed suspensions for the Te Pāti Māori MPs who did a haka during voting on the Treaty Principles Bill - before the Government moved to adjourn it. Despite this, former co-leader Te Ururoa Flavell has spoken in defence of Te Pāti Māori. "The bigger kaupapa here is around an ability for Māori to express their views in the Parliament of our land - and allow that to happen on the back of what has happened through history in Parliament." LISTEN ABOVESee omnystudio.com/listener for privacy information.

The Greens' Chlöe Swarbrick says tax policy has been used before to create a better society. The Greens today launched their alternative Budget, which includes a 2.5 percent tax on individual net wealth over $2 million. It would help pay for policies like free GP trips, free ECE and an Income Guarantee. Swarbrick says after World War Two, higher taxes helped fund public housing and schools. "That created a period by which even those who were having a hard time were able to participate in society and get the necessary social mobility so that they could live a good life in the future." LISTEN ABOVESee omnystudio.com/listener for privacy information.

The Greens are revealing parts of their alternative budget - set to cost about $8 billion over four years. It's calling for a Ministry of Green Works, a Government agency supporting sustainable infrastructure - including regional forestry. The party estimates it would create 40,000 jobs. Co-leader Chlöe Swarbrick won't release more details - but says their costed independent budget will be released in about two weeks. "In about a fortnight's time, we'll be unveiling our Green budget, which will show people how we can have an economy that reduces the cost of living, improves quality of life and also reduces climate-changing emissions." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Plus: At the San Diego zoo, elephants go viral when video captures their touching and fascinating reaction to an earthquake.  Also: Filmmaker Sepideh Farsi on the death of her new documentary's subject: 25 year old Gazan photojournalist Fatima Hassouna, reported killed in an Israeli airstrike.

The federal election is in two weeks, on April 28 – so the Decibel has invited the leaders from Canada's major parties onto the show to share their vision for the country.And while environmental concerns haven't been top-of-mind in this election … Green Party co-leader Jonathan Pedneault says he isn't just concerned about climate change.Pedneault – who previously served as the party's deputy leader from 2022 to 2024 – is proposing bold policies on a range of issues Canadians are facing, from U.S. President Donald Trump's tariff threats to the high cost of living.The former journalist and human rights investigator, who has spent the better part of the last decade and a half working and living abroad, believes more progressive ideas are needed in this election. But the Greens are lagging in the polls, and Pedneault is running in a Liberal stronghold … So how will they be effective if they don't make it to the House of Commons?Today, Green Party co-leader Jonathan Pedneault joins us from Montreal. Ahead of the leader debates this Thursday, we ask him about his party's daring proposals, what the Greens are offering Canadians, and if he's returning to Canadian politics for good.Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com

Green MP Benjamin Doyle has addressed the response to their use of the word "bussy" on Instagram calling it baseless, personal, and violent. Green Party Leader Chloe Swarbrick spoke to Paddy Gower.

David Seymour's responding to a post evoking him as needing trimming like a lawn. Te Pāti Māori co-leader Rawiri Waititi re-shared his partner's post showing him cutting the grass. The caption read: 'I told him to behave as though every piece of grass is a David Seymour. The lawns are getting a good effing hiding.' Seymour says that's objectionable - with its suggestion of attacking a person you disagree with. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Doug McHoney (PwC's International Tax Services Global Leader) is joined by Pat Brown, an International Tax Partner and Co-Leader of PwC's Washington National Tax Services practice. Together, they unpack the state of US corporate tax policy in 2025, analyzing how regulatory, legislative, and geopolitical forces could shape the next era of taxation. Doug and Pat dissect the final regulations issued in the closing days of the Biden administration, including the controversial disregarded payment loss (DPL) regulations, finalized and proposed digital content and cloud sourcing rules, and updates on corporate basis-shifting transactions. With a new administration in power, they explore whether these rules will stand, be modified, or be repealed entirely—and what this means for business certainty and planning. The conversation then pivots to legislative challenges, as the expiration of key provisions from the 2017 Tax Cuts and Jobs Act (TCJA) creates a ticking time bomb for tax policy.  Finally, they tackle the international tax front, where the US f administration responds to the OECD's Pillar Two and potential digital services tax (DST) retaliation under new proposals like Section 899.  

Der Besenwagen rattert endlich wieder über belgisches Kopfsteinpflaster! Rechts, links, rauf und runter fahren wir quer durch Flandern bis nach Ettelgem bei Brügge. Magnus Rex steht mit wedelndem Schwanz vor der Haustür, begrüßt uns herzlichst und auch Herrchen Laurenz ist froh uns zu sehen. Der Belgier mit deutschen Wurzeln geht als Co-Leader für Intermarché-Wanty beim Opening Weekend an den Start und gibt uns eine kleine Einführung in das berühmte Wochenende seiner Heimat.

In this exciting new segment of our Rewind series, we're crafting a Pharmacy Survival Guide that only Catalyst can deliver. These thoughtfully designed multi-part podcasts look back at previous episodes of Catalyst and Beyond the Scripts to explore fundamental areas in pharmacy that will enhance your professional growth. Part 1 of the survival guide focuses on financial foundations & compliance, featuring valuable advice and fresh insights from our previous guests Brad Gallagher, Shahida Choudhry, and Greco De Valencia as they break down critical topics ranging from the importance of working capital in pharmacy transactions to identifying legal blind spots in regulatory compliance.  Links to Previous Episodes Compliance Financial Foundations  00:07 Financial Segment Begins 07:44 Pharmacy Market Trends   11:40 Business Adaptation Strategies   15:37 Acquisition Evaluation  22:41 Compliance Segment Begins28:41 Annual Compliance Requirements   36:38 Hiring Best Practices    Hosted By: Mark Bivins, Chief Growth Officer at RedSail Technologies, Will Tuft | Director of Pharmacy Education & Engagement   Guests: Brad Gallagher | Partner and Co-Leader of Health Care Controversies at Barclay Damon LLP, Shahida Choudhry | Owner of Palms Pharmacy, Greco De Valencia | Senior Loan Officer & Vice President at Pharmacy at Live Oak Bank  Looking for more information about independent pharmacy? Visit www.pioneerrx.com  

Māori Development Minister Tama Potaka's new-look Waitangi Tribunal has been labelled a "whitewash" by Te Pāti Māori. Te Pāti Māori co-leader Debbie Ngarewa-Packer.

This week on Facing the Future, we discuss the budgetary priorities and procedural hurdles facing the new Republican majority in Congress as they try to quickly enact an ambitious agenda. Our guest is Rohit Kumar, Co-Leader of the National Tax Office at PricewaterhouseCoopers and a former senior advisor to Senate Republican leaders.

Prophetic Warning: Not all healing ministries are safe! Melia shares a testimonial of volunteering and co-leading an event for a healing ministry, which brought unexpected challenges and demonic attacks. Melia shares a tidbit from her new audiobook, Fear Not, as she delves into the unsettling journey of a Jezebel spirit who was serving as a leader on the healing ministry team. A powerful reminder of the importance of spiritual discernment not seen by the naked eye! **Chapters** 1. **00:00:00 - Volunteering for Healing Ministry** 2. **00:02:15 - Warm Welcome and Group Division** 3. **00:05:30 - Co-Leader's Dominating Personality** 4. **00:08:45 - Understanding the Jezebel Spirit** 5. **00:12:00 - Private Room Healing Sessions** 6. **00:15:20 - Encountering an Evil Presence** 7. **00:18:40 - Disruptive Prayers and Uncontrollable Crying** 8. **00:22:10 - Husband's Concern and Locked Room** 9. **00:25:30 - Co-Leader's Demanding Behavior** 10. **00:28:50 - Feeling Unsafe and Unsettled** 11. **00:32:10 - Realizing the Presence of Evil** 12. **00:35:30 - Physical Symptoms and Seeking Help** 13. **00:38:50 - Mentors' Assistance and Prayers** 14. **00:42:10 - Leaders' Acknowledgment and Apology** 15. **00:45:30 - Gradual Lifting of the Evil Spirit** 16. **00:48:50 - Lesson on Spiritual Preparedness**   Blessings xo- Melia's Services -> https://meliadiana.com/our-services Melia's Books ->https://meliadiana.com/books Melia's Courses -> https://meliadiana.com/vertical-relationship-academy FREE Resources - > https://meliadiana.com/resources    

"If we can move from a place of fear to a place of curiosity — from a place of resisitance to a place of learning — we'll get a lot farther. We'll enjoy the process a lot more if we can be in the space of learning and curiosity rather than fear and resistance." Fan favorite Emily Saul returns to the Ali on the Run Show to hold all of our hands as we navigate end-of-year stress and navigate new-year anxieties. Emily is a licensed mental health counselor, sport psychology coach, and founder of E Saul Movement. She's a former Division-1 collegiate rower, she's a lifelong athlete, she's a many-time marathoner, and she's a TEDxBoston speaker. FOLLOW EMILY @emilysaulboston SPONSOR:  New Balance: Click here to shop New Balance's latest releases for the season. In this episode: Why you should listen to Emily's advice (6:20) Emily's advice for how to handle end-of-the-year anxiety, and the comparison trap of it all (11:00) Why Emily says we all need to get off the “hedonic treadmill” (23:45) How to approach goal setting in the new year (32:45) “I'm afraid to push myself too hard” (43:10) “It's cold and dark and I can't get myself up and out the door” (1:07:50) Emily on the Ali on the Run Show: Beyond the Run with Emily Saul, Marathon Mentality Q&A Part I Beyond the Run with Emily Saul, Marathon Mentality Q&A Part II Beyond the Run with Emily Saul, Marathon Mentality Q&A Part III LIVE at the Boston Marathon with Emily Saul & Anoush Arakelian Beyond the Run with Dr. Ian Nurse & Emily Saul Emily Saul, Co-Leader of November Project Boston Follow Ali: Instagram @aliontherun1 Join the Facebook group Twitter @aliontherun1 Support on Patreon Subscribe to the newsletter SUPPORT the Ali on the Run Show! If you're enjoying the show, please subscribe and leave a rating and review on Apple Podcasts. Spread the run love. And if you liked this episode, share it with your friends!

Recorded live at the 2024 IRMI Construction Risk Conference, host Jason Reichl sits down with Adrian Pellen, Managing Director & Co-Leader of NFP's North American Construction & Infrastructure Group. With over 20 years of experience in the industry, Adrian leads NFP's construction and infrastructure team across the U.S. and Canada, bringing deep expertise in risk management and insurance solutions for complex construction projects.

In this episode of Beyond the Scripts, host Will Tuft sits down with Brad Gallagher and Shahida Choudhry to explore critical legal considerations often overlooked by pharmacy owners. From contract negotiations to employee management and digital presence guidelines, this is an episode you don't want to miss. Tune in to hear about hard-learned lessons about common legal pitfall to ensure your pharmacy's legal health. 0:00 - Introduction and NCPA event discussion 4:03 - Legal blind spots in regulatory compliance  13:32 - Employee hiring and background check considerations 29:43 - Contract negotiations with PBMs and vendors  9:16 - Documentation and standard operating procedures 44:42 - Digital presence and marketing guidelines 52:01 - Looking ahead to 2025 and closing advice Register for Connect 2025 today! https://redsail.us/4ffLZrD Hosted By: Will Tuft | Manager of Event Education at PioneerRx Guest: Brad Gallagher | Partner and Co-Leader of Health Care Controversies, Barclay Damon LLP Shahida Choudhry | Owner of Palms Pharmacy  Looking for more information about independent pharmacy? Visit www.pioneerrx.com

Guest host Tim Pawlenty talks local politics with Rep. Lisa Demuth.

The Treaty Principles Bill has passed its first reading in Parliament. The first reading was filled with interjections and heckling by Opposition MPs before the vote was cast. Te Pāti Māori co-leader Debbie Ngarewa-Packer spoke to Ingrid Hipkiss.

Last week we celebrated our 100th episode of the show with another live event! James was joined by Co-Leader of the Green Party, Carla Denyer MP, and economists Faiza Shaheen, and Grace Blakeley, to break down Labour's Autumn Budget. A massive thank you to everyone who joined us at Space4! Apologies to anyone awaiting our ELECTION ECONOMICS episode with Thea Riofrancos - we've had to delay that recording but we'll be posting a review of the election results once they are in. As always you'll find that at patreon.com/macrodose.  Got a question or comment? Reach us at macrodose@planetbproductions.co.uk For more about the work we do at Planet B Productions, go to planetbproductions.co.uk

Darleen Tana has been officially ejected from parliament making the Greens the first party to use the waka-jumping provision. Corin Dann spoke to Party Co-leader Chloe Swarbrick

In this episode, Justin and Sean take on your questions about youth ministry and do their best to answer them. They hit topics like:●      Discipline in youth ministry●      Depression in ministry●      Delegation●      Lowest point in youth ministry for us●      Message prep●      When it's time to leave the church●      Follow up with new students●      And more!  Episode sponsor: xpscripture.com   Join the YM Hacks Instagram Channel: https://ig.me/j/Ababaue99NXURdiv/     Check out Co-Leader! Coleader.co

Let us know your views now - text us hereHistory in the making! This is the UK's first regular mainstream show for bisexuals. Hosted by bi activist and writer Lewis Oakley and bisexual journalist Ashley Byrne with comedian and actor Samantha Baines, Bisexual Brunch is a unique podcast for people from all over the world who identify as bi to come together and celebrate their sexuality.  Bisexual Brunch along with former host Nichi Hodgson, Ashley and Lewis were included in the UK Pride Power List  2021. Lewis managed to stay in the list in 2022 and soared to No 79 while MIM, the production company behind Bisexual Brunch was also named UK Production Company of the Year 2021 (Silver winner). Most recently it was revealed Bisexual Brunch's listening figures are in the top 3% of podcasts worldwide - and the show reaches 108 countries, more than half the world! Number One in Kenya.A bumper edition for Bi Month - Ashley and Lewis are joined by the founders of the very first Bi-visibility Day back in 1999.  Find out how it wasn't called that back then from Wendy Curry and Ladyboy Gigi Wilbur. The bisexual special guest is co-leader of the Scottish Greens Patrick Harvie. Meanwhile as Scotland emerges as the bi nation of the UK (at least in population terms) we stay in Scotland for our main bi journey story from Nick Cook in Dundee. Lewis and Ashley discuss ideological zealotry around LGBT issues, there's an Ask a Bisexual question from a woman whose husband recently came out to her and Ashley and Lewis discuss whether there's such a thing as bi-dar or bi fi.Bisexual Brunch is produced by Ashley Byrne and researched by Andrew Edwards and the team at MIM.The show is recorded in Manchester and London in Great Britain.Bisexual Brunch is a Made in Manchester ProductionWe need your support to continue making Bisexual Brunch. Every show costs in time and money. We no longer use Patreon, so if you support us there, we would prefer it if you moved to this method  (click 'support the show' below) - OR via Buy me a Coffee at buymeacoffee.com/info59Support the show

Native-American spiritual and cultural consultant Renee Sans Souci talks about being a lost and confused child living between indigenous and white American culture and her awakening to a Native spiritual tradition and wisdom. Sans Souci also talks about the Missing and Murdered Indigenous Women movement and her own traumatic encounters.With a degree in education from the University of Nebraska-Lincoln and being an Umonhon woman, Renee Sans Souci is a Cultural Consultant, Lecturer, and Curriculum Developer, and has since 2009 been a Teaching Artist with the Lied Center for Performing Arts. She has been invited to speak on topics such as Water and Environmental Science, Missing and Murdered Indigenous Women advocacy, Native Science, History of Indian Education, and Native languages, Poetry, and Sustainability. Sans Souci was featured in the PBS American Masters Series, UNLADYLIKE 2020: Susan LaFlesche Picotte: The First American Indian Doctor. She is also a Co-Leader for the Niskithe Prayer Camp and is a recipient of the UNL Institute of Ethnic Studies 2023 Leo Yankton Award for Indigenous Justice.

The Greens pulled off an all-time best performance in the 2024 General Election, doubling their vote share to a historic high of 6.4% and winning four MPs. But can they handle the transition from outsiders to effective Parliamentary party? How do they square the need to remake Britain as a low-carbon economy and the traditional Green suspicion of development? And can they peel away disillusioned left voters from Labour? Co-leader Carla Denyer talks to Andrew Harrison about another green world.     • “Rachel Reeves' line that ‘there is no money' is pretty misleading… This is one of the richest economies in the world.”  • “There are policies everyone agrees on… but only the Greens are offering them.”      Support us on Patreon to get early access to all our live tickets plus mugs, t-shirts and more.     Presented by Andrew Harrison. Produced by Jade Bailey. Theme music by Cornershop. Managing Editor: Jacob Jarvis. Group Editor: Andrew Harrison. OH GOD, WHAT NOW? is a Podmasters production.    www.podmasters.co.uk Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Samantha Maragh is Leader of the Genome Editing Program and Co-Leader of the Biomarker and Genomic Sciences Group at the U.S. National Institute of Standards and Technology (NIST). She also represents the U.S. as a technical expert on nucleic acid measurements for the International Standards Organization (ISO) Technical Committee on Biotechnology (ISO TC 276). Scientists at NIST work to develop controls and standards to make sure that measurements, tools, and all of the systems that rely on them are correct. Samantha's work focuses particularly on genome editing, which has a variety of applications, including new treatments for diseases, agriculture, and more. When she's not working, Samantha loves cooking and enjoying food, especially seafood. For her, cooking is like science, but even more flexible and creative. Some of her other favorite pastimes include singing at her church on Sundays and playing puzzle games like Best Fiends. Samantha received her B.S. degree in Biology with a specialization in Cellular & Molecular Biology and a minor in chemistry from Loyola University. She went on to get her M.S. degree in Biotechnology: Molecular Targets & Drug Discovery from Johns Hopkins University and her Ph.D. in Human Genetics & Molecular Biology from Johns Hopkins School of Medicine. In 2019, Samantha received the Outstanding Young Scientist Award from The State of Maryland, The Maryland Academy of Sciences, and the Maryland Science Center. She was also selected as the recipient of the George A. Uriano Award in 2021 for her success in building the NIST Genome Editing Consortium as a public-private partnership. In 2022 she received the Measurement Science Excellence Award from the NIST Material Measurement Laboratory for leading the development of the first international standard for the field of genome editing published in 2021 and deploying the first inter-laboratory study for the genome editing field. In this interview, she talks more about her life and science.

Welcome to another episode of Live UNREAL podcast! In this webinar episode, Jeff Glover welcomes Greg Erlanger, Co-Leader of the no. 1 Real Estate Team in Ohio, to share how to become a celebrity in your local market by harnessing the power of video to build your brand and business.  So much of the marketing space has changed, especially in Real Estate. Greg is a marketing master who knows the power of video in Real Estate Marketing today.  The Glover U mission is to impact the lives of millions by helping them live their UNREAL life! We hope you are inspired by the Live Unreal Formula! Whether you're an established Realtor or new to the real estate game, this podcast is designed to empower you with knowledge and inspiration.